List of Diagnostics Companies in Minnesota - 11

Access Genetics, LLC is a privately held Minnesota-based company founded in 2001 by Dr. Ronald McGlennen, an internationally recognized molecular diagnostics expert with over a decade of experience in implementing and developing molecular genetic laboratories. As a medical technology service company, we offer turnkey solutions to assist laboratories in the implementation of molecular genetic testing by recommending a tailored, cost-effective and state-of-the-art suite of hardware, software, prepackaged materials and supplies, process guides, custom tools, staff training, technical support, telemedicine interpretations, and other optional consultative services. This comprehensive service package makes Access Genetics unlike other companies in the genetic testing market that may only provide a piece of the testing puzzle. Our Mission is to improve the availability and utility of diagnostic genetic testing through a base of laboratory providers using our Web-Enabled DNA Testing Model. We partner with qualified clinical labs to enable them to build a quality in-house molecular genetics program that is simple, fast, economical and complete.

AngioInsight, Inc. is a digital health company based in Ann Arbor, Michigan, specializing in artificial intelligence for cardiovascular diagnostics. Founded in 2018, the company develops AI-driven solutions aimed at improving the accuracy and efficiency of diagnosing and managing coronary artery disease (CAD). The AngioAI+ platform is a key offering, designed for real-time assessment during angiography. It provides actionable insights by detecting microvascular dysfunction and quantifying stenosis severity. Additionally, AngioInsight offers fully automated angiogram analysis, which processes coronary angiogram videos to support clinicians in making informed treatment decisions. The company's technology integrates seamlessly into existing clinical workflows, enhancing resource allocation and patient outcomes. AngioInsight has received significant funding, including grants and investments, to support its innovative approach. The company is actively engaged in clinical studies to validate its platform's efficacy, particularly in addressing diagnostic gaps in cardiovascular care. Its solutions are targeted at cardiologists and healthcare institutions that perform millions of angiograms annually.

For more than 50 years, ARKRAY has been committed to producing safe, reliable, effective products; from developing the world's first HbA1c Analyzer, to the first blood glucose monitoring system for Long-Term Care. Today, ARKRAY manufactures cost-effective diabetes care products and clinical chemistry equipment that are simple, convenient and easy-to-use, and also serves as a private-label blood glucose meter manufacturer for the world's largest retailer. ARKRAY prides itself on putting customer service first, with personalized training, industry expertise and on-going support.

Celcuity is a clinical stage biotechnology company that discovers previously undetectable cancer drivers and develops drugs to treat them.

CoraVie Medical's implantable, continuous blood pressure monitor informs treatment decisions to improve lives. The end to end solution improves patient compliance to monitoring and improves blood pressure reliability and actionability. By monitoring trends over day and night, CoraVie enables timely notification of changing health status.

Geneticure optimizes prescription drug therapy by using patients’ DNA to guide their blood pressure treatment with a new, actionable tool, supported by clinical evidence to help you provide even better care for your hypertension patients.

GRIP Molecular is developing a novel, patent-protected, chip-based electronic biosensor that will provide lab-grade diagnostic results in minutes using a mobile device at the point of need. Unlike existing diagnostic technologies, it has the capability to simultaneously detect various diseases and characterize their state of infection (infectious to immune) with a single test. GRIP uses a combination of novel nanomaterials and patented 3D printing to deliver accurate results in minutes without the burden of complex chemistry. The appearance of COVID-19 as a global health threat has increased the urgency to transform diagnostics, which the GRIP team was well into even before this threat emerged. The ability to quickly, easily and cost-effectively test for active infection and immunity at the point of need has become the new baseline for what we should expect for early detection of all kinds of disease, but particularly when fighting a pandemic level enemy. GRIP is committed to confirm the science and commercialize a new approach with a number of specific panels/products that address our most challenging diseases and chronic conditions.

Immune IQ has developed, in collaboration with Honeywell, the Immune Reveal platform. It reads disease information from a patient's immune system in 5 minutes to rapidly identify critical diseases, many not detectable today. Our powerful diagnostic approach has a much lower cost-per-test, a greater range of disease identification, and a shorter time to results than other cellular- and mRNA-based approaches. Immune IQ's initial focus is sepsis, one of the world's greatest healthcare challenges.

OneOme, co-founded by Mayo Clinic, is working to help providers incorporate pharmacogenomics into patient care by offering the RightMed Test and associated tools. The RightMed Test may help providers optimize medication selection for their patients by analyzing and reporting on 27 genes. OneOme is privately held, based in Minneapolis, MN. For more information, visit www.oneome.com and follow us here for updates.

Phenomix Sciences is a precision medicine obesity biotechnology company on a mission to conquer obesity globally through the use of proprietary testing and personalized lifestyle guidance. The company offers the MyPhenome™ test, exclusively licensed from Mayo Clinic, which measures DNA and metabolites related to obesity to improve weight-loss effectiveness. Phenomix Sciences is committed to advancing the understanding of obesity treatment through precision medicine and believes in the power of knowledge and accurate diagnosis.

Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) immunoassay tests and microarrays. Surmodics is pursuing highly differentiated medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements.